The FDA approved Tenpoint Therapeutics’ Yuvezzi, the first dual‑agent eye drop for presbyopia combining carbachol and brimonidine. Tenpoint also closed $235 million in combined equity and debt financing to support commercialization and market launch. Regulators cleared Yuvezzi as a differentiated topical approach vs single‑mechanism drops, and Tenpoint said proceeds include a $150 million senior secured loan and $85 million in series B equity. The company plans to use funds for marketing, product supply and distribution. For ophthalmology and med‑tech investors, the approval validates combination topical approaches for presbyopia and underlines the financing appetite for novel, near‑market ophthalmic therapeutics backed by clear regulatory paths.